Sun Pharma Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries, and Glenmark are contesting over their right to use drug names “Istamet” and “Indamet”, respectively, which Sun Pharma finds to be deceptively similar and confusing.
